
Francesco Morra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9237393/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neuropilin-1 Expression Associates with Poor Prognosis in HNSCC and Elicits EGFR Activation upon CDDP-Induced Cytotoxic Stress. Cancers, 2021, 13, 3822.	3.7	3
2	The tumour suppressor CCDC6 is involved in ROS tolerance and neoplastic transformation by evading ferroptosis. Heliyon, 2021, 7, e08399.	3.2	3
3	NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells. Cancers, 2020, 12, 44.	3.7	4
4	Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma. Lung Cancer, 2019, 135, 56-65.	2.0	14
5	Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors. International Journal of Molecular Sciences, 2019, 20, 3100.	4.1	32
6	CAF-1 Subunits Levels Suggest Combined Treatments with PARP-Inhibitors and Ionizing Radiation in Advanced HNSCC. Cancers, 2019, 11, 1582.	3.7	11
7	CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 90.	8.6	29
8	CCDC6: the identity of a protein known to be partner in fusion. International Journal of Cancer, 2018, 142, 1300-1308.	5.1	26
9	USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs. Lung Cancer, 2017, 107, 41-49.	2.0	51
10	The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy. International Journal of Molecular Sciences, 2017, 18, 1374.	4.1	47
11	The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells. Oncotarget, 2017, 8, 31815-31829.	1.8	51
12	Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. Journal of Experimental and Clinical Cancer Research, 2016, 35, 179.	8.6	88
13	FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC. Oncotarget, 2015, 6, 12697-12709.	1.8	42
14	New therapeutic perspectives in <scp>CCDC</scp> 6 deficient lung cancer cells. International Journal of Cancer, 2015, 136, 2146-2157.	5.1	41